Revised July 2017



Invasive Meningococcal Infection (*Neisseria meningitidis*) Investigation Form

Complete in addition to the Notification of Infectious Disease Form (EPI-1). In the event of an outbreak additional forms and specimen collection are required for testing, a VIDOH-EPID staff will coordinate additional paperwork and investigation.

*** All dates follow mm/dd/yyyy format ***

Case Status: ☐ Confirmed ☐ Probable ☐ Suspect ☐ Not a Case	□STX □STT □STJ □WI			
Patient's name: Last First MI	Reported by:			
Address:	Agency:			
City: *STATE: Zip:	Phone: ()Date reported://			
Phone 1: () Phone 2: ()	NBS Patient ID: NBS Investigation ID:			
Date of birth:// Age: Sex: □Male □Female □Unk	Investigated by:			
Race: □White □Black □Asian □Pacific Islander □Native American/Alaskan	Agency:			
□Unknown □ Other: Hispanic: □ Yes □ No □ Unknown	Phone: ()			
	Email:			
Parent/guardian's name:	Investigation start date://			
* If USVI resident, please indicate ESTATE :	Date investigation completed://			
CLINICAL DATA				
Symptom onset date:/ Illness end date:/				
Did patient die? ☐ Yes, died on:// ☐ No, but still ill ☐ N	o, recovered			
Signs and symptoms (Check all that apply):				
□ Fever □ Sensitivity to light □ Stiff neck □ Headache □ Nausea □	Vomiting □ Diarrhea □ Chills □ Confusion □ Fatigue			
□ Rash, pinpoint red spots (petechiae) □ Purple, bruise-like areas (purpura) □ Cold hands/feet □ Muscle pain □ Joint pain				
□ Abdominal pain □ Shortness of breath □ Chest pain □ Cough □ Seizures □ Other:				
Clinical presentation (Check all that apply):				
\square Bacteremia \square Meningitis \square Pneumonia \square Septic arthritis \square Cellulitis	☐ Pericarditis ☐ Osteomyelitis ☐ Purpura fulminans			
□ Bacteremia □ Meningitis □ Pneumonia □ Septic arthritis □ Cellulitis □ Other:	☐ Pericarditis ☐ Osteomyelitis ☐ Purpura fulminans			
•	☐ Pericarditis ☐ Osteomyelitis ☐ Purpura fulminans Physician's phone: ()			
□ Other:				
□ Other: Physician's name:	Physician's phone: ()			
□ Other: Physician's name: UNDERLYING CONDITIONS	Physician's phone: ()			
□ Other: Physician's name: UNDERLYING CONDITIONS Does the patient have any underlying health conditions? □ Yes (check all the	Physician's phone: () at apply)			
□ Other: Physician's name: UNDERLYING CONDITIONS Does the patient have any underlying health conditions? □ Yes (check all the patient have any underlying disease □ Diabetes □ End stage renal disease	Physician's phone: () at apply)			
□ Other:	Physician's phone: () at apply)			
□ Other:	Physician's phone: () at apply)			
□ Other:	Physician's phone: () at apply)			
□ Other:	Physician's phone: () at apply)			
□ Other:	Physician's phone: ()			
□ Other: Physician's name: UNDERLYING CONDITIONS Does the patient have any underlying health conditions? □ Yes (check all the □ Asthma □ Other chronic lung disease □ Diabetes □ End stage renal dise □ Asplenia (functional or anatomic) □ Complement component deficiency/inhibit Other prior illness within two weeks of onset? □ Yes, specify: HEALTH BEHAVIORS (record in underlying conditions in NBS) Do any of the following apply to the patient? □ Yes (check behaviors below) □ □ Current smoker □ Alcohol, drinks per week: □ □ Intravenous drug underlying the patient receive antibiotics? □ Yes, one □ Yes, multiple □ No □ TREATMENT HISTORY	Physician's phone: ()			
□ Other:	Physician's phone: () at apply)			
□ Other:	Physician's phone: ()			
□ Other:	Physician's phone: ()			
□ Other:	Physician's phone: ()			
Does the patient have any underlying health conditions? ☐ Yes (check all the disconsisting of the patient have any underlying health conditions? ☐ Yes (check all the disconsisting of the patient have any underlying health conditions? ☐ Yes (check all the disconsisting of the patient characteristic) ☐ Complement component deficiency/inhibitions of the prior illness within two weeks of onset? ☐ Yes, specify:	Physician's phone: ()			

Pt. Name:	NBS Pt. ID: Jurisdiction:						
HOSPITALIZATION INFORMATION Was the patient hospitalized? Yes, name of hospital: Unknown					Unknown		
Date of admission:// Date of discharge://							
How many people were in the vehic	cle that trans	ported the patient to the	hospital?				
Was the patient seen at multiple ho	ospitals? ☐ \	′es □ No □ Unknow	n If y	es, complete the	following table:	T 1	
Hospital / Clinic name		Mode of transportation to facility Date/time of visit/arrival			Date/time of discharge	Discharged to*	
	□ dro	□ drove self □ driven by friend/family □ ambulance □ other:					
	□ dro	☐ drove self ☐ driven by friend/family ☐ ambulance ☐ other:					
* discharged to home, another facility,	or left again	st medical advice (AMA))	<u>I</u>			
VACCINATION HISTORY		,					
History obtained from: ☐ Patient/Pa	arent 🗆 Prin	nary care physician □ F	Reporting physic	ian/facility □ Sc	hool □ lmmTrac l	☐ Other:	
Has the patient ever received any m	neningococo	cal vaccine? □ Yes, fill	in table below	□ No □	☐ Unknown*		
Dose # Date dose received	Vacci	ne Manufacturer	Vaccine	Brand/Name	Vaccine Lot Number		
1							
2							
3//							
*Note: All possible sources of vaccina	tion history a	bove should be exhaust	ted before decid	ling that vaccinat	ion status is "unkno	own".	
Timeline for meningococcal disease	е	Contacts	s eligible for				
			ohylaxis				
-10 Da	avs -7 l	Days	Symptom Onset	Antibiotics given +24	l Hours		
10 20		ન	Oliset		\neg		
	」	_ 		┸			
l)		
		Infectious Pe	eriod				
ADDITIONAL EXPOSURE HISTORY	,						
Did the patient travel anywhere dur		weeks prior to onset a	nd up until the	patient was dia	gnosed/treated?	☐ Yes ☐ No ☐ Unk	
Travel location:	_	-	-	-	//_ to _		
Travel location:							
Travel location: Dates of travel: //							
Travel location: Dates of travel:/ to// to//							
Did the patient spend 8 or more hours on an airplane (or bus, train, etc.)? ☐ Yes, complete line(s) below ☐ No ☐ Unknown							
Airline: Flight number: Flight date:/_ / Time:: Departure city:							
Airline: Flight number: Flight date:/ / Time::_ Departure city:							
Did the patient attend any gatherings (e.g., public, church/religious, family, etc.), conventions, meetings, parties, dinners, sporting events,							
festivals, or other group events dur	ing the two	weeks prior to onset?	☐ Yes, comp	lete the following] Unknown	
Event		L	ocation		# of people present	Date of event	

Pt. Name:		NBS Pt. II	D:	Jurisdi	ction:		
CONTACTS Refer to the last page for	,						
For the following questions, please ask a							<u>y treated.</u>
Where was the patient living? ☐ Single-f	, ,		•			•	
☐ Military barracks ☐ Hospital or rehab fa☐ Shelter/halfway house ☐ Camp ☐ O	•	•				•	
How many people live in the patient's ho	usehold?						
How many people did the patient							
Kiss? Share a sleeping area with?	Share	e a toothbrush wi	th? Shar	e food or uten	sils with?	_ Share drinks	s with?
Share (brass or wind) band instruments with? Share cigarettes with? Share drugs with?							
Did the patient perform mouth to mouth	resuscitation	on anyone? \Box	Yes □ No [□ Unknown			
If yes, name of person:			Date perforr	ned :/	_/		
Did the patient attend, visit, or work at a	school? 🗆 Y	es, student 🛭 🗅 🗅	Yes, faculty/staff	☐ Yes, visit	or 🗆 No 🏻	□ Unknown	
lf a college student, college year: □ Fr ∶l	□So □Jr [□ Sr □ Other	Liv	e in a dorm? 🛭] Yes □ No	□ Unknown	
Did the patient attend, stay, visit, or worl	cat a childcar	e center, home	daycare, nursin	g home, or si	milar facility?	Yes □ No	□ Unk
If yes, school/facility name:			Date last	attended/worke	ed/visited befor	re onset:/	
Total contacts (#):students/reside	entsst	aff ·	Total close conta	icts (#):	_students/resid	dentsst	aff
Did anyone associated with the facility ha	ve a similar illi	ness during the t	wo weeks prior to	o onset? □ Ye	s □No □U	Jnknown	
If yes, name of person:			Date of ons	et/	/ If nee	eded, attach list i	to this report
Was the patient in a detention center or	correctional fa	acility (e.g., jail,	prison, etc.)?	□ Yes, name:_		□ No	☐ Unknown
Is the patient employed? ☐ Yes ☐ No	□ Unknowr	1					
Occupation:		Name/location	n of employer:				
Date last worked before treatment:/							
During the two weeks prior to onset, did	any member	of the patient's	household have	a similar illn	ess? □ Yes	□ No □ Ur	ıknown
If yes, name of person:			Date of onse	et/			
If yes, name of person:			Date of onse	et/			
SEXUAL CONTACTS							
Please ask the patient the following ques	stions:						
During the past 12 months, have you ha	ad sex with or	nly males, only f	females, or with	both males a	nd females?		
☐ Males only ☐ Females only ☐	Both males and	d females □ U	Jnknown □ I	Refused to ans	wer		
Do you consider yourself to be: ☐ Hetero	sexual/Straight	□ Gay/Lesbia	n/Homosexual	□ Bisexual □	Other:		□ Refused
Thinking back to the 3 months before you w	ere diagnosed	with meningoco	ccal disease, how	many MEN die	d you have sex	with during that	time?
Number of men: (Known □ Estir	mated) □ U	nknown (no numb	per given)	☐ Refused to	answer	
PROPHYLAXIS							
Date prophylaxis recommendations were	_				-		
Prophylaxis provided by (check all that ap	oply): U DSH	SorLHD ⊔ Ho	spital ⊔ Privati	e physician L	J Other:		☐ None given
Number of people	Household	Students at school &/or daycare	Staff at school &/or daycare	Residents at long term care facility	Staff at long term care facility	Healthcare workers including EMS	Other close contacts*
Prophylaxis recommended for:							
Declined recommended prophylaxis:							
Received prophylaxis:							
* Friends, colleagues, extended family, etc.							

Pt. Name:NE	SS Pt. ID: Jurisdiction:
LABORATORY DATA	
Isolate sent to DSHS (required)? ☐ Yes, on/; DS	HS#:
Was Neisseria meningitidis testing done?	
\square Yes, complete sections below \square No, diagnosis based on cl	inical purpura fulminans Other:
Gram stain:	
Date and time collected://;:□AM	□PM Specimen Source: □ CSF □ Blood □ Other:
Result: ☐ Gram-negative diplococci ☐ Negative ☐	nconclusive Unknown Other:
	ce: mm H ₂ O
Glucose: mg/dL Protein: mg/dL RBCs: Culture:	mm³ WBCs: mm³ Lymphs: % Polys: % Mono: %
Date and time collected://;:□AM	
Result: ☐ Positive for: ☐ N	egative □ Inconclusive □ Unknown □ Other:
Other test:	
Test type: ☐ Latex agglutination ☐ Immunohistochemistr	y (IHC) □ PCR □ Other:
Date and time collected:/;: □AM	
Result: ☐ Positive for: ☐ ☐ I	Negative □ Inconclusive □ Unknown □ Other: □ Other: □Not groupable □ Unknown □ Pending
	OL MEASURES IMPLEMENTED (check all that apply and indicate date initiated)
	recautions until 24 hours after effective antibiotic treatment on//
☐ Reviewed high risk exposures with medical provider on/_	
 □ Contact tracing (identifying close contacts through patient or su □ Education (risk, transmission, symptoms) provided to contacts 	,
☐ Requested the hospital or laboratory forward the isolate to the □	•
☐ Worked with school, daycare or long term care facility to identify	
□ Other (specify):	•
	on / /
- Curior (opcorny)	
COMMENTS	

PROPHYLAXIS RECOMMENDATIONS

THE FOLLOWING GROUPS OF INDIVIDUALS SHOULD RECEIVE CHEMOPROPHYLAXIS AFTER EXPOSURE TO **MENINGOCOCCAL DISEASE**

Groups of individuals recommended to receive prophylaxis after to exposure with a person with invasive meningococcal disease:

- All close family contacts, household members, and anyone who frequently slept in the same dwelling as the case.
- Classroom contacts in the preschool, childcare center, or childcare home attended by the case.
- Persons directly exposed to infectious oral secretions without personal protective equipment (PPE) including through kissing, sharing utensils, sharing toothbrushes, or unprotected mouth to mouth resuscitation, intubation, or suctioning procedures
- Passengers seated directly next to the case during airline flights lasting 8 hours or more.

It is important that antimicrobial chemoprophylaxis be administered as soon as possible, ideally within 24 hours. The incubation period is 1 to 10 days. Chemoprophylaxis given more than 14 days after exposure is of limited value.

When prophylaxis is indicated, it should be administered to all eligible contacts at the same time to eliminate the organism from the population. Prophylaxis should begin within 24 hours of diagnosis or strong suspicion of case. Culturing of contacts is not recommended. Prophylaxis should not substitute for close observation of case contacts for symptoms. Refer to the current American Academy of Pediatrics Red Book for prophylaxis dosages.

Prophylaxis is not recommended for casual contacts without direct exposure to the patient's oral secretions (e.g., work or school, except as noted above). All contacts should be provided education on risk, transmission, and symptoms.